BioAge Labs, Inc. (BIOA)

Current Report Filed: 2026-05-08

Key Insights

• BioAge Labs announced Q1 2026 financial results on May 8, 2026, with the actual earnings data contained in the referenced press release (Exhibit 99.1), which is not included in this 8-K filing itself.
• The company is classified as an emerging growth company, indicating it is still in early stages of development and may have reduced disclosure obligations, though it has opted not to use the extended transition period for accounting standards.
• Dov Goldstein, M.D., signed as Chief Financial Officer, suggesting the company has established formal financial leadership for quarterly reporting and SEC compliance.
• The 8-K filing is relatively routine procedural disclosure for earnings announcement with standard safe harbor language, indicating no material corporate events, acquisitions, leadership changes, or other significant developments beyond quarterly results.

Sentiment: Neutral Significance: 3/10

View Original Filing →

Quarterly Report Filed: 2026-05-08

Key Insights

• The filing is heavily populated with structured data tags but the actual narrative content is truncated, making it impossible to assess key financial metrics, revenue trends, or operational performance for Q1 2026.
• Multiple references to collaborative arrangements with Novartis Pharma AG and an At-The-Market offering program with Leerink Partners suggest the company is actively pursuing partnerships and capital raising strategies.
• The presence of loan and security agreement references to SVB Innovative Credit Growth Funds indicates existing debt financing arrangements that warrant examination for covenant compliance and liquidity implications.
• Insider stock option and warrant activity is documented across multiple equity plans (2015, 2024), but without actual transaction details or valuations, the significance of insider confidence or compensation trends cannot be determined.

Sentiment: Neutral Significance: 3/10

View Original Filing →

Insider Trading Filed: 2026-04-24

Key Insights

• CFO Dov Goldstein acquired 3,542 shares of common stock at $4.38 per share on April 23, 2026, bringing his total beneficial ownership to 36,575 shares, indicating confidence in the company's valuation at this price point.
• The transaction includes a stock option grant of 3,542 shares with the same exercise price ($4.38), featuring a standard 4-year vesting schedule with monthly increments (1/48th per month), beginning February 1, 2025, which is typical executive compensation structure.
• This insider purchase by a C-suite executive (CFO) during the April 2026 timeframe suggests management's positive outlook on the company, though the transaction appears to be primarily option/equity compensation rather than a voluntary market purchase.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-04-03

Key Insights

• The reporting person, Paul D. Rubin, exercised stock options and immediately sold the resulting shares, indicating potential liquidation of his stake in the company.
• The transactions were executed pursuant to a pre-established Rule 10b5-1 trading plan, suggesting planned and systematic insider selling.
• The exercise prices of $4.11 and $6.57 are significantly lower than the reported sale price of $17.81, potentially signaling favorable market conditions or growth prospects for the company.

Sentiment: Neutral Significance: 6/10

View Original Filing →

Annual Report Filed: 2026-03-24

Key Insights

• BioAge Labs, Inc. (BIOA) has entered into a collaborative arrangement with Novartis Pharma AG, which could provide additional revenue streams and strategic partnerships.
• The company has secured a loan and security agreement with SVB Innovative Credit Growth Fund IX, LP and Innovative Credit Growth Fund VIII, ALP, providing additional financing to fund operations.
• BioAge Labs has implemented an at-the-market (ATM) sales agreement with Leerink Partners LLC to raise additional capital through equity offerings.

Sentiment: Positive Significance: 7/10

View Original Filing →

Current Report Filed: 2026-03-24

Key Insights

• BioAge Labs, Inc. reported its financial results for the year ended December 31, 2025, indicating the company's performance during that period.
• The company has updated its corporate deck, which is now available on its investor relations website, providing additional information for investors.
• BioAge Labs, Inc. is an emerging growth company, meaning it may take advantage of certain regulatory exemptions and disclosures.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-03-03

Key Insights

• The reporting person, Paul D. Rubin, the Chief Medical Officer of BioAge Labs, Inc., exercised 7,433 stock options at an average exercise price of $5.34 and sold all of the resulting shares at $20.3 per share.
• The stock option exercises and sales appear to be part of a Rule 10b5-1 trading plan, indicating a planned and structured approach to managing the reporting person's equity holdings.
• The reporting person continues to hold 3,383 remaining stock options, suggesting an ongoing commitment to the company and alignment with shareholder interests.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-03-03

Key Insights

• Dov A. Goldstein, the Chief Financial Officer of BioAge Labs, Inc. (BIOA), exercised 3,542 stock options at an exercise price of $4.38 per share on March 1, 2026.
• Goldstein's total beneficial ownership of BIOA common stock increased to 33,033 shares following the transaction, indicating his continued commitment to the company.
• The option exercise was part of Goldstein's compensation package and likely aligns his interests with those of BIOA shareholders.

Sentiment: Positive Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-02-19

Key Insights

• Paul D. Rubin, the Chief Medical Officer of BioAge Labs, Inc. (BIOA), has acquired 110,000 stock options with an exercise price of $19.63 and a vesting period of 4 years, indicating his long-term commitment to the company.
• The options grant suggests that the company is incentivizing its key executives to drive the company's growth and development, aligning their interests with those of shareholders.
• Insider transactions like this can provide insights into management's confidence in the company's future prospects and their alignment with shareholders' interests.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-19

Key Insights

• Eric Morgen, the Chief Operating Officer of BioAge Labs, Inc., acquired 110,000 stock options and 12,500 stock options granted to his spouse, indicating insider confidence in the company's prospects.
• The stock options are subject to a 4-year vesting schedule, with the first tranche vesting on February 1, 2026, aligning Morgen's interests with long-term shareholder value creation.
• The exercise price of the options is $19.63, which suggests the company's management believes the stock is undervalued and presents an attractive investment opportunity for insiders.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-02-19

Key Insights

• Dov A. Goldstein, the Chief Financial Officer of BioAge Labs, Inc. (BIOA), has acquired 110,000 stock options with an exercise price of $19.63 and a vesting period of 4 years.
• The acquisition of these options suggests that Goldstein is confident in the company's future growth and is willing to take a long-term stake in the organization.
• The significant number of options granted to Goldstein, a key executive, may indicate that BioAge Labs is focusing on incentivizing and retaining its leadership team to drive the company's success.

Sentiment: Positive Significance: 6/10

View Original Filing →

Insider Trading Filed: 2026-02-19

Key Insights

• Kristen Fortney, the CEO of BioAge Labs, acquired 330,000 stock options on February 17, 2026, suggesting strong insider confidence in the company's future prospects.
• The options vest monthly over a 4-year period, aligning Fortney's incentives with long-term shareholder value creation.
• This transaction represents a significant increase in Fortney's beneficial ownership, potentially signaling her commitment to the company's success.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-02-19

Key Insights

• The reporting person, Shane Barton, who is the Principal Accounting Officer, acquired 45,000 stock options with an exercise price of $19.63 and a 10-year expiration date.
• The options vest monthly over 4 years, indicating the company is providing long-term equity incentives to its key accounting officer.
• The timing of the option grant suggests the company is making strategic investments in its finance and accounting team to support its ongoing operations and future growth.

Sentiment: Positive Significance: 6/10

View Original Filing →

Current Report Filed: 2026-01-22

Key Insights

• BioAge Labs, Inc. is raising approximately $107.6 million in net proceeds from a public offering of its common stock, which it plans to use for research, clinical development, manufacturing, and other general corporate purposes.
• The company is focused on developing product candidates, including BGE-102 and its NLRP3 and APJ programs, which could potentially treat cardiovascular risk and other age-related diseases.
• The public offering is being conducted under a shelf registration statement, indicating the company's ability to access the capital markets to fund its ongoing operations and growth initiatives.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-01-21

Key Insights

• Dov A. Goldstein, the Chief Financial Officer of BioAge Labs, Inc. (BIOA), exercised 3,542 stock options at an exercise price of $4.38 on January 16, 2026.
• Goldstein's exercise of these options increased his direct beneficial ownership of BIOA common stock to 25,950 shares.
• The options exercised had an expiration date of February 17, 2035, and vested monthly over a four-year period starting from February 1, 2025.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Current Report Filed: 2026-01-20

Key Insights

• BioAge Labs announced the expansion of its oral NLRP3 inhibitor BGE-102 into a Phase 1b/2a proof-of-concept clinical trial for diabetic macular edema (DME), a significant inflammation-driven retinal disease.
• The preclinical data showed that BGE-102 demonstrated dose-dependent preservation of retinal vascular integrity and up to 90% preservation of microvascular integrity in a DME model.
• BioAge plans to initiate the DME trial in mid-2026, following the completion of the ongoing Phase 1 trial and the initiation of a Phase 2a proof-of-concept trial in patients with obesity and cardiovascular risk factors.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-01-15

Key Insights

• Kristen Fortney, the CEO of BioAge Labs, Inc. (BIOA), has sold 233,107 shares of the company's common stock on January 13, 2026, at a weighted average price of $18.1163 per share.
• The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than an opportunistic sale.
• Following the reported transaction, Fortney still holds 976,949 shares of the company's common stock, suggesting she maintains a significant ownership position.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-01-15

Key Insights

• The reporting person, Dov A. Goldstein, who is the Chief Financial Officer of BioAge Labs, Inc., exercised 27,000 stock options and then sold 27,000 shares of the company's common stock on January 13, 2026.
• The reported sales were executed pursuant to a Rule 10b5-1 trading plan, suggesting planned and structured insider selling rather than opportunistic trades.
• The average sale prices ranged from $18.43 to $21.08 per share, indicating the CFO was able to sell the shares at favorable market prices.

Sentiment: Neutral Significance: 5/10

View Original Filing →

Current Report Filed: 2026-01-12

Key Insights

• BioAge Labs announced positive interim Phase 1 data for BGE-102, a novel NLRP3 inhibitor, showing rapid and profound reductions in inflammatory markers like hsCRP and IL-6 in obese individuals with elevated cardiovascular risk.
• The company achieved an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels, indicating BGE-102's potential as a best-in-class treatment for reducing cardiovascular risk.
• BioAge expects to complete the Phase 1 trial and initiate a Phase 2a proof-of-concept study in patients with obesity and cardiovascular risk factors in the first half of 2026, which could further validate BGE-102's therapeutic potential.

Sentiment: Positive Significance: 8/10

View Original Filing →

Insider Trading Filed: 2026-01-06

Key Insights

• The Chief Medical Officer, Paul D. Rubin, exercised stock options and sold a significant amount of shares, potentially signaling a change in his outlook or a need for liquidity.
• The options exercised and shares sold were pursuant to a pre-established 10b5-1 trading plan, indicating the transactions were planned in advance.
• The timing of the transactions, occurring at the start of the year, may provide insight into management's views on the company's near-term prospects.

Sentiment: Neutral Significance: 6/10

View Original Filing →